10 Result(s)

Article

Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial

This study evaluated azacitidine as treatment of minimal residual disease (MRD) determined by a sensitive donor chimerism analysis of CD34⁺ blood cells to pre-empt relapse in patients with CD34⁺ myelodysplastic s...

U Platzbecker, M Wermke, J Radke, U Oelschlaegel, F Seltmann, A Kiani, I-M Klut… in Leukemia (2012)

Article

Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study

U Platzbecker, F Braulke, A Kündgen, K Götze, G Bug, C Schönefeldt… in Leukemia (2013)

Article

Relationship of different platelet response criteria and patient outcomes in a romiplostim myelodysplastic syndromes trial

U Platzbecker, M A Sekeres, H Kantarjian, A Giagounidis, G J Mufti, C Jia… in Leukemia (2014)

Article

Myelodysplasia is in the niche: novel concepts and emerging therapies

Myelodysplastic syndromes (MDSs) represent clonal disorders mainly of the elderly that are characterized by ineffective hematopoiesis and an increased risk of transformation into acute myeloid leukemia. The pa...

E Bulycheva, M Rauner, H Medyouf, I Theurl, M Bornhäuser, L C Hofbauer… in Leukemia (2015)

Article

Clonal architecture of del(5q) myelodysplastic syndromes: aberrant CD5 or CD7 expression within the myeloid progenitor compartment defines a subset with high clonal burden

U Oelschlaegel, M Alexander Röhnert, B Mohr, K Sockel, S Herold, G Ehninger… in Leukemia (2016)

Article

A phase 3 randomized placebo-controlled trial of darbepoetin alfa in patients with anemia and lower-risk myelodysplastic syndromes

The use of darbepoetin alfa to treat anemia in patients with lower-risk myelodysplastic syndromes (MDS) was evaluated in a phase 3 trial. Eligible patients had low/intermediate-1 risk MDS, hemoglobin ⩽10 g/dl,...

U Platzbecker, A Symeonidis, E N Oliva, J S Goede, M Delforge, J Mayer, B Slama… in Leukemia (2017)

Article

CRISPR/Cas9-edited NSG mice as PDX models of human leukemia to address the role of niche-derived SPARC

I Tirado-Gonzalez, E Czlonka, A Nevmerzhitskaya, D Soetopo, E Bergonzani… in Leukemia (2018)

Article

Correction: CRISPR/Cas9-edited NSG mice as PDX models of human leukemia to address the role of niche-derived SPARC

An amendment to this paper has been published and can be accessed via a link at the top of the paper.

I. Tirado-Gonzalez, E. Czlonka, A. Nevmerzhitskaya, D. Soetopo, E. Bergonzani… in Leukemia (2021)

Article

Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification—an approach to classification of patients with t-MDS

In the current World Health Organization (WHO)-classification, therapy-related myelodysplastic syndromes (t-MDS) are categorized together with therapy-related acute myeloid leukemia (AML) and t-myelodysplastic...

A. Kuendgen, M. Nomdedeu, H. Tuechler, G. Garcia-Manero, R. S. Komrokji… in Leukemia (2021)

Article

Efficacy and safety of bemcentinib in patients with advanced myelodysplastic neoplasms or acute myeloid leukemia failing hypomethylating agents- the EMSCO phase II BERGAMO trial

A. S. Kubasch, P. Peterlin, T. Cluzeau, K. S. Götze, K. Sockel, R. Teipel… in Leukemia (2023)